Trial Profile
A phase IIa study to evaluate the relative efficacy and safety/tolerability of a single agent vs. a combination treatment for reducing saliva secretion in Parkinson's disease patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs Clonidine (Primary) ; Clonidine/oxybutynin (Primary) ; Oxybutynin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Summit Therapeutics
- 10 Aug 2011 New trial record